STAT

2018 in limericks: The highs and lows from the life sciences

What a year it's been in the life sciences: CRISPR babies and IPOs galore, high-priced CAR-Ts and gene therapies. We remember it all with the 2018 edition of our year…

It’s been an eventful year in the life sciences, from the struggles of IBM Watson, to China’s twin CRISPR surprise, to a flurry of IPOs, to catching a serial killer with.)

Stai leggendo un'anteprima, registrati per continuare a leggere.

Altro da STAT

STAT1 min lettiScience
STAT Plus: Pharmalittle: Sanofi To Cut Hundreds Of Jobs; Former BARDA Chief Claims Azar Is Sabotaging His New Job
Sanofi is considering cutting hundreds of jobs and will discuss potential steps with staff representatives over the coming days.
STAT1 min letti
STAT Plus: Pharmalittle: Moderna Executives Cashed Out Big Time; Should We Have ‘Quality Scores’ For Manufacturing Drugs?
A group of academics and pharmacists argue that assigning scores based on a mix of regulatory actions and chemical analysis would motivate drug makers to produce more “quality” drugs.
STAT1 min letti
STAT Plus: Phlow CEO Speaks Out On Criticism Of His Record, Plans For A Drug Ingredient Stockpile, And A Huge Government Contract
STAT spoke with Phlow CEO Eric Edwards about the criticism over his track record, Phlow's plan to create a national drug ingredient stockpile, and the huge government contract the company…